Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis

Phase 2 Terminated 2 enrolled Allergan

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with painful bladder syndrome/interstitial cystitis

Timeline

Start: 2006-10
Primary completion: 2007-03
Completion: 2007-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	REZATOMIDINE	Small molecule	—	—

Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis

Summary

Timeline

Drugs

Indications